Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- Novartis to Divest Flu Vaccine Biz within 18 Months
May 28, 2014
- DSP Grants Daiichi Sankyo Commercialization Rights to Lurasidone in South America
May 28, 2014
- GSK Files Long-Acting COPD Drug for Approval in Japan
May 27, 2014
- Taisho Toyama to Center on Safety for Lusefi Promotion: Product Manager
May 27, 2014
- GSK Launches Tenozet, a First-Line Option for the Treatment of Chronic Hepatitis B
May 27, 2014
- DSP Ceases PIII Colorectal Cancer Trial for Anticancer Agent BBI608
May 27, 2014
- Concurrent Use Restrictions Lifted for 3 DPP-4 Inhibitor Products
May 27, 2014
- Chugai Concludes Deal with Roche for Chugai’s Antibody Engineering Technologies
May 27, 2014
- Daiichi Sankyo, US Research Institute to Collaborate in Developing Cardiovascular-Metabolic Disease Treatments
May 26, 2014
- 3 More SGLT-2 Inhibitors Make Japan Debuts to Trail Suglat
May 26, 2014
- Astellas Launches Anticancer Drug Xtandi Capsules in Japan
May 26, 2014
- Three Companies Including DSP Jointly Invest 845 Million Yen in Create Vaccine
May 26, 2014
- Teikoku Seiyaku Licenses Antiallergic Treatment from Uriach of Spain
May 26, 2014
- Foreign Drug Makers’ Japan Units Underperform Market Growth in 2013
May 23, 2014
- Blopress AG Rollout Won’t Coincide with June Listing: ASKA Pres.
May 23, 2014
- 5 of 17 Pharmacy Chains Settle April-June Delivery Prices via Qol-Led Open Tender
May 23, 2014
- Teva Pharma Japan to Postpone NHI Price Listing of All Generics Including Valsartan in June
May 23, 2014
- JPMA Code Committee to Discuss Actions against Kyowa Kirin, Novartis over Improper Involvement in Clinical Trials
May 22, 2014
- Takeda’s UC, CD Treatment Entyvio Approved in US
May 22, 2014
- EPS Did Nothing Wrong in Data Verifications for VART Study Probe: Pres.
May 21, 2014
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…